GLP-1 receptor agonist medications are becoming one of the fastest-adopted drug classes in pharmaceutical history, with more than eight million Americans currently prescribed semaglutide or tirzepatide for weight loss or diabetes management. The drugs's demonstrated cardiovascular benefits have expanded their clinical indications beyond obesity, creating a potential patient pool that could eventually number in the tens of millions.
The economic implications for the healthcare system are profound. The drugs cost between 900 and 1,400 dollars monthly before insurance, a price that is straining pharmacy benefit budgets and forcing difficult coverage decisions at employers and insurers. Proponents argue that reduced costs from prevented cardiovascular events, joint replacements, and diabetes complications will generate net savings over time. Actuaries are skeptical that the math works at the scale of adoption being projected.
